Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixen…
3 weeks, 6 days ago
The Ron Lanton Report: Where Innovations Happens
In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastruct…
3 weeks, 6 days ago
Pharmaceutical Executive Daily: Idvynso Receives FDA Approval
In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight…
4 weeks ago
Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast
In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results, …
4 weeks, 1 day ago
Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics
In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues a…
1 month ago
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michae…
1 month ago
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-appro…
1 month ago
Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement
In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therape…
1 month ago
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $74…
1 month ago
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and T…
1 month, 1 week ago